Treatment  Subgroups  (Male) Treatment  Subgroups  (Female)   Week AML HCZ AML HCZ Gender  Effect 0 30.30 ± 0.63 31.50 ± 0.98 31.00 ± 0.54 29.50 ± 0.76 0.0003*** 1 30.50 ± 0.58 31.20 ± 0.98 31.40 ± 0.47 29.70 ± 0.70 3 32.00 ± 0.92B 30.00 ± 0.92 31.40 ± 0.45 28.70 ± 0.67 6 32.21 ± 0.47B 31.10 ± 0.97 32.50 ± 0.44aB 28.80 ± 0.66 b 12 32.90 ± 0.53B 31.10 ± 0.95 33.10 ± 0.41aB 27.40 ± 0.59b 24 33.80 ± 0.42aB 30.00 ± 0.86b 34.30 ± 0.41aB 27.50 ± 0.59b 36 34.20 ± 0.44aA 29.70 ± 0.92b 35.30 ± 0.42aA 28.20 ± 0.67b 48 35.60 ± 0.40aA 29.20 ± 0.62b 36.40 ± 0.42aA 28.90 ± 0.62b Significant differences within columns are indicated by AB and within rows by ab, (P<0.05): Demonstrated are significant treatment effects and time-dependent increase (AML subgroups) and decrease (HCZ subgroups) in high density lipoprotein cholesterol concentrations which are higher in males; ***P< 0.001; other abbreviations are as used in table 2; (N=10 per subgroup)

Table 5: Effects of monotherapy with AML and HCZ on high density lipoprotein cholesterol (mg/dl) in diabetic hypertensive subjects for 48 weeks.